These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38229093)

  • 21. Evaluation of the Histopathological Features of Early-stage Invasive Ductal Breast Carcinoma by
    Erol M; Önner H; Eren Karanis Mİ
    Mol Imaging Radionucl Ther; 2021 Oct; 30(3):129-136. PubMed ID: 34658227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Added value of dedicated axillary hybrid 18F-FDG PET/MRI for improved axillary nodal staging in clinically node-positive breast cancer patients: a feasibility study.
    van Nijnatten TJA; Goorts B; Vöö S; de Boer M; Kooreman LFS; Heuts EM; Wildberger JE; Mottaghy FM; Lobbes MBI; Smidt ML
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):179-186. PubMed ID: 28905091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation analysis of 18F-FDG PET/CT for the staging and treatment effect assessment of breast cancer.
    Li Y; Dai Y; Guo Y; Wang J; Duan X
    J Xray Sci Technol; 2019; 27(6):1131-1144. PubMed ID: 31561405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Semi-quantitative lymph node assessment of (18)F-FDG PET/CT in locally advanced breast cancer: correlation with biological prognostic factors.
    García Vicente AM; Soriano Castrejón A; Cruz Mora MA; González Ageitos A; Muñoz Sánchez Mdel M; León Martín A; Espinosa Aunión R; Relea Calatayud F; Muñoz Madero V; Chacón López-Muñiz I; Cordero García JM; Jiménez Londoño GA
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):72-9. PubMed ID: 23053321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
    Song BI; Lee SW; Jeong SY; Chae YS; Lee WK; Ahn BC; Lee J
    J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased Prostate Cancer Glucose Metabolism Detected by
    Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
    Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2-fluoro-2-deoxy-D-glucose positron emission tomography versus conventional imaging for the diagnosis of breast cancer and lymph node metastases.
    Shao M; Zi J; Wen G
    J Cancer Res Ther; 2018 Sep; 14(Supplement):S661-S666. PubMed ID: 30249884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes.
    Kim JY; Lee SH; Kim S; Kang T; Bae YT
    Eur Radiol; 2015 Apr; 25(4):1172-81. PubMed ID: 25298170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDG-PET for axillary lymph node staging in primary breast cancer.
    Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from
    Kim YI; Kim YJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kang KW
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1787-1795. PubMed ID: 28616695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry.
    Utech CI; Young CS; Winter PF
    Eur J Nucl Med; 1996 Dec; 23(12):1588-93. PubMed ID: 8929312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic and volume-based parameters of (18F)FDG PET/CT for primary mass and axillary lymph node metastasis in patients with invasive ductal carcinoma: a retrospective analysis in relation to molecular subtype, axillary lymph node metastasis and immunohistochemistry and inflammatory markers.
    Can C; Komek H
    Nucl Med Commun; 2019 Oct; 40(10):1051-1059. PubMed ID: 31365497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology?
    Basu S; Mavi A; Cermik T; Houseni M; Alavi A
    Mol Imaging Biol; 2008; 10(1):62-6. PubMed ID: 18000713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The relationship between (18)F-FDG PET/CT metabolic parameters and clinicopathological features of breast cancer].
    Tang B; Zhang Y; Zhou J; Xu Y; Li TR; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2017 Apr; 39(4):280-285. PubMed ID: 28550668
    [No Abstract]   [Full Text] [Related]  

  • 36. Prognostic significance of preoperative
    Higuchi T; Nishimukai A; Ozawa H; Fujimoto Y; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Kitajima K; Fukushima K; Miyoshi Y
    Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of GLUT-1, SGLT-1, and SGLT-2 expression in false-negative and true-positive lymph nodes during the
    Taira N; Atsumi E; Nakachi S; Takamatsu R; Yohena T; Kawasaki H; Kawabata T; Yoshimi N
    Lung Cancer; 2018 Sep; 123():30-35. PubMed ID: 30089592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.
    Ueda S; Tsuda H; Asakawa H; Omata J; Fukatsu K; Kondo N; Kondo T; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
    BMC Cancer; 2008 Jun; 8():165. PubMed ID: 18541009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer.
    van der Hoeven JJ; Hoekstra OS; Comans EF; Pijpers R; Boom RP; van Geldere D; Meijer S; Lammertsma AA; Teule GJ
    Ann Surg; 2002 Nov; 236(5):619-24. PubMed ID: 12409668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer.
    Ahn JH; Son EJ; Kim JA; Youk JH; Kim EK; Kwak JY; Ryu YH; Jeong J
    Acta Radiol; 2010 Oct; 51(8):859-65. PubMed ID: 20670083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.